Article
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Blood - 15 Mar 2008
Davies Stella M, Borowitz Michael J, Rosner Gary L, Ritz Kristin, Devidas Meenakshi, Winick Naomi, Martin Paul L, Bowman Paul, Elliott James, Willman Cheryl, Das Soma, Cook Edwin H, Relling Mary V
Abstract excerpt
Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy. Within known prognostic categories, the determinants of MRD are not known. We measured MRD by flow cytometry at day 8 (in blood) and at day 28 (in bone marrow) of induction therapy in more than 1000 children enrolled in Pediatric Oncology Group...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.